

**Article type:** Original Research Article

**Title:** Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

**Authors:** Sherko Kuemmel<sup>1,2\*</sup>, Carlo A. Tondini<sup>3</sup>, Jacinta Abraham<sup>4</sup>, Zbigniew Nowecki<sup>5</sup>, Bartosz Itrych<sup>6,†</sup>, Erika Hitre<sup>7</sup>, Bogusława Karaszewska<sup>8</sup>, Alejandro Juárez-Ramiro<sup>9</sup>, Flavia Morales-Vásquez<sup>10</sup>, Jose Manuel Pérez García<sup>11‡</sup>, Servando Cardona-Huerta<sup>12</sup>, Estefania Monturus<sup>13</sup>, Marco Sequi<sup>14,15§</sup>, Eleonora Restuccia<sup>13</sup>, Mark Benyunes<sup>16</sup> and Miguel Martín<sup>17</sup>

**Author affiliations:**

<sup>1</sup> Breast Unit, Kliniken Essen-Mitte, Essen, Germany

<sup>2</sup> Clinic for Gynecology with Breast Center, Charité – Universitätsmedizin Berlin, Berlin, Germany

<sup>3</sup> Department of Onco-Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy

<sup>4</sup> Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK

<sup>5</sup> Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Centrum Onkologii-Instytut, Warsaw, Poland

<sup>6</sup> Department of Oncology, Magodent, Warsaw, Poland

<sup>7</sup> Department of Medical Oncology and Clinical Pharmacology “B”, National Institute of Oncology, Budapest, Hungary

<sup>8</sup> Przychodnia Lekarska KOMED, Konin, Poland

<sup>9</sup> Medical Oncology, CME Consultorio de Medicina Especializada, Mexico City, Mexico

<sup>10</sup> FUCAM, Instituto Nacional de Cancerología de Mexico, Mexico City, Mexico

<sup>11</sup> Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>12</sup> Centro de Cáncer de Mama, Hospital Zambrano-Hellion, Tecnológico de Monterrey, Monterrey, Mexico

<sup>13</sup> Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland

<sup>14</sup> Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

<sup>15</sup> Biostatistics, PAREXEL, Milan, Italy

<sup>16</sup> Global Product Development, Genentech, Inc., South San Francisco, CA, USA

<sup>17</sup> Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain

**\* Corresponding author:** Sherko Kuemmel, MD, PhD

**Address:** Breast Unit, Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany

**Telephone:** +49-201-174-33001

**Email:** [s.kuemmel@kem-med.com](mailto:s.kuemmel@kem-med.com)

**† Current address:** Department of Oncology and Hematology, Central Clinical Hospital MSWiA, Warsaw, Poland (Itrych)

‡ **Current address:** International Breast Cancer Center (IBCC), Quiron Group, Barcelona,  
Spain (Pérez García)

§ Current address: CROS Academy, Bologna, Italy (Sequi)

**Target journal:** *Breast Cancer Research and Treatment*

## Online Resource 5 – Objective response rate

	H SC + P IV + D IV (n = 336)
ORR, no. (%) [95% CI]	254 (75.6) [70.64–80.09]
CR	42 (12.5)
PR	212 (63.1)
Non-responders, no. (%)	27 (8.0)
PD	17 (5.1)
Not evaluable	1 (0.3)
Missing	9 (2.7)
Stable disease, no. (%)	55 (16.4)
CBR	309 (92.0)

*CBR* clinical benefit rate, *CI* confidence interval, *CR* complete response, *D IV* intravenous docetaxel, *H SC* subcutaneous trastuzumab, *ORR* objective response rate, *PD* progressive disease, *P IV* intravenous pertuzumab, *PR* partial response

Data are number of patients (%) [95% CI]